Abeona Therapeutics Inc Q2 2021 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Kristen Brianne Kluska - Cantor Fitzgerald & Co., Research Division - Analyst : Congrats on the Type B meeting outcome. The first one I have is, could you remind us about the latest efforts and the current database for natural history in MPS IIIB. And given that for MPS IIIA, you've achieved the best results when treating early in the high dose cohort. How should we also be thinking about perhaps the long-term data in Cohort 2, given that these patients are actually receiving a higher dose than MPS IIIA.

Question: Kristen Brianne Kluska - Cantor Fitzgerald & Co., Research Division - Analyst : Sure. But also the focus was on Cohort 2 for MPS IIIB, just given that the protocol for the MPS IIIB trial includes higher doses relative to what you're studying for MPS IIIA .

Question: Kristen Brianne Kluska - Cantor Fitzgerald & Co., Research Division - Analyst : Yes. And then moving on to ABO-102. Is there a specific time line to follow-up that you're looking to collect for the more recently treated patients in Cohort 3 as it relates to your comments about having a potential pivotal package next year?

Question: Kristen Brianne Kluska - Cantor Fitzgerald & Co., Research Division - Analyst : Appreciate that. And then the last question on the same program. In regards to the brain MRI data you recently shared, were there any other measurements conducted at time points besides 24 months? And then just looking across these 3 patients in good detail now that you have some neurocognitive finding biomarkers in this data as well. Could you talk about how all of these endpoints are correlating with each other?